Sylentis is an European biotechnological company founded in 2006. Sylentis focuses on researching new therapeutic approaches based on gene silencing. Our company is specialised in developing ophtalmologic   therapies via interference RNA, a powerful tool for rational drug design.

Most advanced product of the company are treatments for glaucoma and dry eye syndrome.

Sylentis is a wholly owned member of PharmaMar (www.pharmamar.com)

Biotechnology

Health Care

Life Sciences

Therapeutics

SYLENTIS

SYLENTIS' headquarters in Tres Cantos, Spain

Andreas Segerros

This department focuses on innovating and improving products through scientific research and experimentation.

Research and Development

This department handles laboratory operations, including testing and analysis to support development processes.

Laboratory Services

This department focuses on overseeing production processes and ensuring product quality standards are met.

Production and Quality

This department focuses on ensuring the quality and compliance of products through rigorous testing and validation processes.

Quality Assurance

This department oversees and provides strategic guidance and leadership at the organizational level.

Board Governance

This department is responsible for overseeing and managing clinical processes to ensure efficient and effective patient care.

SYLENTIS

Org chart

Teams

Research and Development

Laboratory Services

Production and Quality

Quality Assurance

Board Governance

Clinical Operations

Offices

SYLENTIS

Org chart

Teams

Research and Development

Laboratory Services

Production and Quality

Quality Assurance

Board Governance

Clinical Operations

Offices

Related companies